Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older

Advanced age has been a major limitation of interferon-based treatment for chronic hepatitis C virus (HCV) infection because of its poor response and tolerability. Direct-acting antiviral (DAA) drug regimens are safe and highly effective, allowing administration of treatment also in elderly. This st...

Descripción completa

Detalles Bibliográficos
Autores principales: Trifan, Anca, Stanciu, Carol, Gheorghe, Liana, Iacob, Speranta, Curescu, Manuela, Cijevschi Prelipcean, Cristina, Stefanescu, Gabriela, Girleanu, Irina, Chiriac, Stefan, Mihai, Catalina, Brisc, Ciprian, Goldis, Adrian, Sporea, Ioan, Miftode, Egidia, Bataga, Simona, Rogoveanu, Ion, Preda, Carmen, Caruntu, Florin Alexandru, Singeap, Ana-Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
4500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815789/
https://www.ncbi.nlm.nih.gov/pubmed/29390377
http://dx.doi.org/10.1097/MD.0000000000009271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815789/
https://www.ncbi.nlm.nih.gov/pubmed/29390377
http://dx.doi.org/10.1097/MD.0000000000009271

Ejemplares similares